Tandem Diabetes Care, Inc. is a medical technology company specializing in the design, development, and commercialization of automated insulin delivery systems for people with type 1 and type 2 diabetes. The company’s core products include the t:slim X2 and Tandem Mobi durable insulin pump platforms, both powered by the Control-IQ+ hybrid closed-loop algorithm. These systems integrate with continuous glucose monitoring sensors from partners such as Dexcom and Abbott to automatically adjust insulin dosing. Tandem also provides single-use supplies, including insulin cartridges and infusion sets, as well as digital tools like the Tandem Source data management platform and the Sugarmate mobile application. The company serves patients globally, with a significant presence in the United States, and collaborates with healthcare providers and researchers to support diabetes therapy management.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage tandemdiabetes.com
Sector Healthcare IR page investor.tandemdiabetes.com
Tags
insulin pumps, automated insulin delivery, diabetes management, closed-loop systems, continuous glucose monitoring integration, medical software, infusion sets, type 1 diabetes, type 2 diabetes, t:slim X2, Tandem Mobi, Control-IQ+, Tandem Source, Sugarmate, Tandem Device Updater, Dexcom G6, Dexcom G7, Abbott FreeStyle Libre 2 Plus, Abbott FreeStyle Libre 3 Plus, Unomedical
Press page —

Metrics

Valuation  
Market cap $ 1.336B
Market cap (USD) $ 1.336B
P/E -27.75
PEG —
P/BV 9.89
P/S 1.24
P/OCF -91.46
P/FCF -36.80
Dividend yield —
Turnover / mcap —
Returns  
ROE -97.9%
ROI -44.0%
ROIC -30.2%
Profit margin -20.2%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 446.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 17
Quality score -76.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 1.015B 940.203M 747.718M 801.217M 702.799M 498.83M 362.305M 183.866M 107.601M 84.248M 72.85M 49.722M 29.007M
Net profit -204.71M -96.025M -222.611M -94.594M 15.566M -34.382M -24.753M -122.611M -73.033M -83.447M -72.418M -79.524M -63.139M
Free cash flow -29.669M 4.994M -58.614M 16.367M 97.179M -2.739M 22.364M -11.305M -71.854M -70.103M -64.528M -65.784M -51.767M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 21.98 36.02 29.58 44.95 150.52 95.68 59.61 37.97 2.35 2.15 11.81 12.7 25.77
Price performance 12m -0.39 0.22 -0.34 -0.7 0.57 0.61 0.57 15.13 0.1 -0.82 -0.07 -0.51 —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 11.2M 20.8M 35.2M 46.6M 82.2M 111M 115M 106M 115M 165M
↳ YoY growth -20.5% +86.1% +69.3% +32.4% +76.4% +34.7% +3.6% -8.0% +8.6% +44.4%
↳ 5y CAGR +53.9% +46.0% +43.5% +42.4% +58.2% +40.7% +24.6% +19.7% +15.0%
Borrowings, current (USD) — — — — — — — 0.00 40.7M —
Borrowings, non-current (USD) 81.1M 82.7M — — — — — 285M 308M 310M
Lease liabilities (USD) — — — 20.4M 25.3M 33.2M 137M 131M 125M 134M
Cash and deposits (USD) 44.7M 13.7M 41.8M 51.2M 94.6M 71.2M 173M 58.9M 69.2M 90.6M
Intangible assets (USD) — — — — — 6.64M 4.63M 2.78M 925,000 11.7M
Right-of-use assets (USD) — — — 15.6M 19.8M 27.5M 111M 87.8M 85.3M 96.2M
Net debt (borrowings + leases - cash) (USD) 36.4M 69M — — — — — 357M 404M 354M
Cash flow detail
Operating cash flow (USD) -61.2M -66.1M -8.32M 41.9M 24.7M 111M 50.5M -31.8M 24.2M -9.72M
Purchases of property, plant and equipment (USD) -8.93M -5.72M -2.99M -19.5M -27.4M -14.2M -34.1M -26.8M -19.2M -19.9M
Purchases of intangible assets (USD) — — 0.00 0.00 -4.89M — — — — —
Change in receivables (cash effect) (USD) 2.25M -10.4M -15.8M -13.7M -38.8M -31M -7.83M 4.28M -20.8M -56.8M
Change in inventories (cash effect) (USD) -6.9M -5.89M 6.76M -31M -15.4M -4.95M -42.5M -46.1M 5.81M 24.8M
Change in payables (cash effect) (USD) 3.23M -1.95M 1.64M 8.91M 1.12M 10.3M 24.5M -4.86M -2.39M 2.23M
Share buybacks (cash effect) (USD) — — — — — — 0.00 0.00 -30M 0.00
Interest paid (cash effect) (USD) -4.4M -7.88M -10.8M 0.00 -2.71M -4.31M -4.31M -7.57M -3.08M -5.05M
Income taxes paid (cash effect) (USD) -23,000 -22,000 -16,000 -67,000 -177,000 -260,000 -411,000 -1.92M -3.1M -5.06M
Share-based compensation (USD) 11.7M 12.6M 23.7M 58.1M 58.4M 60.8M 84.9M 88.1M 101M 92.4M
Operating cash flow before change in receivables (USD) -63.4M -55.7M 7.53M 55.6M 63.5M 142M 58.3M -36.1M 45M 47.1M
Free cash flow (OCF - PPE - intangibles) (USD) -70.1M -71.9M -11.3M 22.4M -7.63M 97.2M 16.4M -58.6M 4.99M -29.7M
Income detail
Research and development expense (USD) 18.8M 20.7M 29.2M 45.2M 63.6M 92.1M 139M 170M 199M 193M
↳ 5y CAGR +17.9% +18.1% +21.4% +23.4% +30.2% +37.4% +46.4% +42.2% +34.5% +24.9%
Total comprehensive income (USD) -83.5M -73M -123M -24.6M -34.3M 14.7M -95.8M -219M -99.3M -197M
Comprehensive income to owners (USD) -83.5M -73M -123M -24.6M -34.3M 14.7M -95.8M -219M -99.3M -197M
Provision for credit losses (USD) 632,000 824,000 1.45M 2.32M 3.02M 2.33M 4.78M 5.54M 9.98M 9.48M
Credit cost ratio (credit losses / average receivables) (%) 5.0% 5.2% 5.2% 5.7% 4.7% 2.4% 4.2% 5.0% 9.1% 6.8%
Reported Mar 8, 2017 Mar 1, 2018 Feb 24, 2021 Feb 24, 2021 Feb 24, 2021 Feb 22, 2023 Feb 26, 2025 Feb 26, 2025 Feb 26, 2025 Feb 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Tandem Diabetes Care, Inc. — Other Events Bull 3 Bear 0 Clinical/regulatory

On November 12, 2026, Tandem Diabetes Care, Inc. (the “Company”) received 510(k) clearance from the U.S. Food and Drug Administration for Tandem Mobi, the world’s first and only tubeless automated insulin delivery system with up to 7 days of wear (1). A new Tandem Mobi tubeless cartridge and infusion set converts the current Tandem Mobi pump into a tubeless device that can help simplify diabetes management with less frequent site changes, while offering the life-changing benefits of Control-IQ+ advanced hybrid closed-loop technology. The Tandem Mobi insulin pump is now cleared for tubeless and tubed insulin infusion options, making it the only pump that offers users the flexibility to choose the wear option that best meets their needs. Full commercial launch of the new tubeless cartridge and infusion set for Tandem Mobi is planned for the first half of 2027 in the United States.

(1) Tubeless infusion set is cleared for up to 7 days of wear. Cartridge is cleared for 3 days of use.

Download PDF

SAN DIEGO--(BUSINESS WIRE)--Nov. 5, 2026-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2026.

Third Quarter 2026 Financial Highlights

  • Sales of $283.7 million worldwide, including $191.0 million in the United States (U.S.)

  • Gross margin of 57%, up 270 basis points compared to third quarter 2025

  • Pump shipments of approximately 33,000 worldwide, including nearly 23,000 pumps in the U.S.

  • Operating margin improved 830 basis points compared to third quarter 2025

  • Scaled pay-as-you-go reimbursement model resulting in 15% of U.S. sales through the pharmacy channel

Third Quarter 2026 and Recent Strategic Highlights

  • Increased pharmacy formulary coverage to approximately 50% of U.S. lives

  • Expanded availability of t:slim X2 compatibility with the Abbott FreeStyle Libre 3 Plus Sensor to 11 international markets

  • Announced international availability of Tandem Mobi in 12 countries

“Tandem’s third-quarter performance demonstrates that our strategy is delivering results,” said John Sheridan, president and chief executive officer. “We are expanding access to Tandem’s life-changing technology, strengthening our business model, advancing our pipeline and driving greater operating efficiency, creating a stronger foundation for sustainable, profitable growth.”

Third Quarter 2026 Financial Results Compared to Third Quarter 2025

  • **Sales:**Worldwide sales increased 14% to $283.7 million, compared to $249.3 million on a reported basis and in constant currency(1).

Sales in the U.S. increased 9% to $191.0 million, compared to $175.6 million.

International sales increased 26% to $92.6 million, compared to $73.6 million. International sales increased 27% in constant currency(1).

Shipments in the U.S. were nearly 23,000 pumps, compared to more than 20,000 pumps.

International shipments were nearly 11,000 pumps, compared to more than 9,000 pumps.

  • Gross profit: Gross profit was $160.4 million, compared to $134.3 million. Gross margin was 57%, compared to 54%.

  • **Operating loss:**Operating loss was $2.4 million, or negative 1% of sales, compared to operating loss of $22.9 million, or negative 9% of sales.

  • Net loss: Net loss was $7.1 million, compared to net loss of $21.2 million.

Adjusted EBITDA(1) was $18.0 million, or 6% of sales, compared to $2.8 million, or 1% of sales.

See tables for additional financial information.

2026 Financial Guidance

For the year ending December 31, 2026, the Company is reaffirming the following financial guidance:

  • Sales are estimated to be approximately $1.065 billion to $1.085 billion

  • U.S. sales of approximately $730 million to $745 million

  • International sales of approximately $335 million to $340 million

  • Gross margin is estimated to be approximately 56% to 57% of sales

  • Adjusted EBITDA margin(2) is estimated to be approximately 5% to 6% of sales

  • Non-cash charges included in cost of goods sold and operating expenses are estimated to be approximately $85 million. This includes:

  • Approximately $65 million non-cash, stock-based compensation expense

  • Approximately $20 million depreciation and amortization expense

For a comprehensive overview of the Company's guidance assumptions for 2026, including pricing and transition assumptions for the adoption of pay-as-you-go reimbursement in the U.S. and the initiation of international direct operations, please see the Events & Presentations tab in the Investor Center of the Tandem Diabetes Care website at https://investor.tandemdiabetes.com.

| (1) | Constant currency sales growth and adjusted EBITDA are non-GAAP financial measures. See “Non-GAAP Financial Measures” below for additional information on these non-GAAP financial measures. A reconciliation of constant currency to GAAP sales can be found in Table C “Sales by Geography and Non-GAAP Reconciliation of Constant Currency Sales Growth” attached to this press release. A reconciliation of adjusted EBITDA to net loss can be found in Table D “Reconciliation of GAAP versus Non-GAAP Financial Results” attached to this press release. |

| (2) | Adjusted EBITDA margin is a non-GAAP financial measure. The Company has not reconciled adjusted EBITDA margin outlook to the most comparable GAAP outlook because it is not possible to do so without unreasonable efforts due to the uncertainty and potential variability of reconciling items, which are dependent on future events and often outside of management’s control and which could be significant. Because such items cannot reasonably be predicted with the level of precision required, the Company is unable to provide outlook for the comparable GAAP measure (net income (loss) as a percentage of sales). Forward-looking estimates of adjusted EBITDA margin are made in a manner consistent with relevant calculations and assumptions noted herein. |

Non-GAAP Financial Measures

Certain financial measures presented in this press release are not calculated or presented in accordance with generally accepted accounting principles (GAAP). The Company has provided these non-GAAP financial measures to provide information that may assist investors in understanding the Company’s financial results and assessing its prospects for future performance. The Company’s management believes these non-GAAP financial measures are important operating performance indicators because they either exclude items that are unrelated to, and may not be indicative of, the Company’s core operating results, or aid in presenting information on a consistent and comparable basis. These non-GAAP financial measures, as calculated, may not necessarily be comparable to similarly titled measures of other companies and may not be appropriate measures for comparing the performance of other companies relative to the Company. These non-GAAP financial results are not intended to represent, and should not be considered to be more meaningful measures than, or alternatives to, financial measures calculated and presented in accordance with GAAP. To the extent the Company uses such non-GAAP financial measures in the future, the Company expects they will be calculated using a consistent method from period to period and, if not, an explanation will be provided.

Adjusted EBITDA and Adjusted EBITDA Margin

Adjusted EBITDA is a non-GAAP financial measure that is calculated by adding back to net loss the following items: income tax expense (benefit); interest income, interest expense and other, net; depreciation and amortization; litigation and settlement expense; stock-based compensation expense; and non-recurring facility impairment and restructuring costs. Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by GAAP sales. A reconciliation of adjusted EBITDA to net loss has been provided in Table D “Reconciliation of GAAP versus Non-GAAP Financial Results” attached to this press release.

Constant Currency Sales Growth

Constant currency sales growth is a non-GAAP financial measure that represents the change in sales between current and prior year periods using the exchange rate in effect during the applicable prior year period. A reconciliation of constant currency to GAAP sales has been provided in Table C “Sales by Geography and Non-GAAP Reconciliation of Constant Currency Sales Growth” attached to this press release.

Conference Call

The Company will hold a conference call and simultaneous webcast today at 4:30pm Eastern Time (1:30pm Pacific Time). The link to the webcast will be available by accessing the Events & Presentations tab in the Investor Center of the Tandem Diabetes Care website at https://investor.tandemdiabetes.com, and will be archived for 30 days. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI99b384cce5da4b33b55d2905f84b8b26) and you will be provided with dial-in details, including a personal pin.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is headquartered in San Diego, California. For more information, visit tandemdiabetes.com.

Tandem Diabetes Care, the Tandem logo, Control-IQ, Control-IQ+, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the U.S. and/or other countries.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements include statements regarding, among other things, the Company’s projected financial results. The Company’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, the Company’s ability to achieve projected financial results will be impacted by market acceptance of the Company’s products; products marketed and sold or under development by competitors; foreign currency exchange rates; the Company’s ability to establish and sustain operations to support international sales, including expanding into additional geographies and going direct in certain markets; changes in reimbursement rates or insurance coverage for the Company’s products; the success of the Company’s sales models and strategies, including the Company’s pay-as-you-go pharmacy channel reimbursement model; the Company’s ability to meet increasing operational and infrastructure requirements from higher customer interest and a larger base of existing customers; the Company’s ability to successfully commercialize its products; the Company’s ability to develop and launch new products; risks associated with the regulatory approval process in the U.S. and internationally for new products; the potential that newer products, or other technological breakthroughs for the monitoring, treatment or prevention of diabetes, may render the Company’s products obsolete or less desirable, or may otherwise negatively impact the purchasing trends of customers; reliance on third-party relationships, such as outsourcing and supplier arrangements; global economic conditions; and other risks identified in the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other documents that the Company files with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors except as required by law.

| |

| TANDEM DIABETES CARE, INC. |

| CONDENSED CONSOLIDATED BALANCE SHEETS |

| Table A |

| (in thousands) |

| | (unaudited) | | | |

| | September 30, | | December 31, |

| | | 2026 | | | | 2025 | |

| Assets | | | | | |

| Current assets: | | | | | |

| Cash, cash equivalents and short-term investments | $ | 443,082 | | | $ | 292,666 | |

| Accounts receivable, net | | 180,022 | | | | 165,491 | |

| Inventories | | 143,121 | | | | 128,769 | |

| Other current assets | | 54,499 | | | | 31,217 | |

| Total current assets | | 820,724 | | | | 618,143 | |

| | | | | | |

| Property and equipment, net | | 85,141 | | | | 83,580 | |

| Operating lease right-of-use assets | | 98,002 | | | | 96,172 | |

| Equity method investment | | 125,538 | | | | 60,351 | |

| Other long-term assets | | 30,089 | | | | 22,866 | |

| Total assets | $ | 1,159,494 | | | $ | 881,112 | |

| | | | | | |

| Liabilities and Stockholders’ Equity | | | | | |

| Current liabilities: | | | | | |

| Accounts payable, accrued expenses and employee-related liabilities | $ | 156,510 | | | $ | 138,488 | |

| Operating lease liabilities | | 20,381 | | | | 19,472 | |

| Deferred revenue | | 8,325 | | | | 9,527 | |

| Other current liabilities | | 70,859 | | | | 75,237 | |

| Total current liabilities | | 256,075 | | | | 242,724 | |

| | | | | | |

| Convertible senior notes, net - long-term | | 603,388 | | | | 310,036 | |

| Operating lease liabilities - long-term | | 112,774 | | | | 114,967 | |

| Deferred revenue - long-term | | 7,595 | | | | 8,474 | |

| Other long-term liabilities | | 44,575 | | | | 49,741 | |

| Total liabilities | | 1,024,407 | | | | 725,942 | |

| | | | | | |

| Total stockholders’ equity | | 135,087 | | | | 155,170 | |

| Total liabilities and stockholders’ equity | $ | 1,159,494 | | | $ | 881,112 | |

| | | | | | | | |

| TANDEM DIABETES CARE, INC. |

| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |

| Table B |

| (in thousands, except per share data) |

| (Unaudited) |

| |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| Sales | $ | 283,690 | | | $ | 249,253 | | | $ | 785,471 | | | $ | 724,353 | |

| Cost of sales | | 123,268 | | | | 114,961 | | | | 343,481 | | | | 345,799 | |

| Gross profit | | 160,422 | | | | 134,292 | | | | 441,990 | | | | 378,554 | |

| Operating expenses: | | | | | | | |

| Selling, general and administrative | | 113,945 | | | | 108,440 | | | | 333,774 | | | | 331,889 | |

| Research and development | | 48,846 | | | | 48,715 | | | | 141,811 | | | | 147,048 | |

| Acquired in-process research and development expenses | | — | | | | — | | | | — | | | | 75,217 | |

| Litigation and settlement expense | | — | | | | — | | | | — | | | | 19,951 | |

| Total operating expenses | | 162,791 | | | | 157,155 | | | | 475,585 | | | | 574,105 | |

| Operating loss | | (2,369 | ) | | | (22,863 | ) | | | (33,595 | ) | | | (195,551 | ) |

| Total other income (expense), net | | (5,324 | ) | | | (2,280 | ) | | | (14,633 | ) | | | (9,403 | ) |

| Loss before income taxes | | (7,693 | ) | | | (25,143 | ) | | | (48,228 | ) | | | (204,954 | ) |

| Income tax expense (benefit) | | (608 | ) | | | (3,978 | ) | | | 418 | | | | (833 | ) |

| Net loss | $ | (7,085 | ) | | $ | (21,165 | ) | | $ | (48,646 | ) | | $ | (204,121 | ) |

| | | | | | | | |

| Net loss per share - basic and diluted | $ | (0.10 | ) | | $ | (0.31 | ) | | $ | (0.70 | ) | | $ | (3.04 | ) |

| | | | | | | | |

| Weighted average shares used to compute basic and diluted net loss per share | | 69,650 | | | | 67,652 | | | | 69,024 | | | | 67,040 | |

| | | | | | | | | | | | | | | | |

| |

| TANDEM DIABETES CARE, INC. |

| SALES BY GEOGRAPHY AND NON-GAAP RECONCILIATION OF CONSTANT CURRENCY SALES GROWTH |

| Table C |

| (Unaudited) |

| | |

| ($'s in thousands) | Three Months Ended****September 30, |

| | 2026 | | 2025 | | % Change | | Currency Impact | | % Change Constant Currency |

| United States: | | | | | | | | | |

| Pump | $ | 83,381 | | $ | 84,785 | | (2 | )% | | | | |

| Supplies and other | | 107,664 | | | 90,846 | | 19 | % | | | | |

| Total Sales in the United States | $ | 191,045 | | $ | 175,631 | | 9 | % | | — | % | | 9 | % |

| | | | | | | | | | |

| International: | | | | | | | | | |

| Pump | $ | 31,575 | | $ | 25,329 | | 25 | % | | | | |

| Supplies and other | | 61,070 | | | 48,293 | | 26 | % | | | | |

| Total International Sales | $ | 92,645 | | $ | 73,622 | | 26 | % | | (1 | )% | | 27 | % |

| | | | | | | | | | |

| Total Worldwide Sales | $ | 283,690 | | $ | 249,253 | | 14 | % | | — | % | | 14 | % |

| | | | | | | | | | |

| ($'s in thousands) | Nine Months Ended****September 30, |

| | 2026 | | 2025 | | % Change | | Currency Impact | | % Change Constant Currency |

| United States: | | | | | | | | | |

| Pump | $ | 244,324 | | $ | 242,393 | | 1 | % | | | | |

| Supplies and other | | 286,856 | | | 254,079 | | 13 | % | | | | |

| Total Sales in the United States | $ | 531,180 | | $ | 496,472 | | 7 | % | | — | % | | 7 | % |

| | | | | | | | | | |

| International: | | | | | | | | | |

| Pump | $ | 95,710 | | $ | 81,683 | | 17 | % | | | | |

| Supplies and other | | 158,581 | | | 146,198 | | 8 | % | | | | |

| Total International Sales | $ | 254,291 | | $ | 227,881 | | 12 | % | | 3 | % | | 9 | % |

| | | | | | | | | | |

| Total Worldwide Sales | $ | 785,471 | | $ | 724,353 | | 8 | % | | 1 | % | | 7 | % |

| | | | | | | | | | |

| |

| TANDEM DIABETES CARE, INC. |

| RECONCILIATION OF GAAP VERSUS NON-GAAP FINANCIAL RESULTS |

| Table D |

| (Unaudited) |

| | | | | | | | |

| ($'s in thousands) | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| GAAP operating loss | $ | (2,369 | ) | | $ | (22,863 | ) | | $ | (33,595 | ) | | $ | (195,551 | ) |

| Litigation and settlement expense | | — | | | | — | | | | — | | | | 19,951 | |

| Non-recurring facility impairment and restructuring costs(1) | | — | | | | — | | | | — | | | | 11,167 | |

| Non-GAAP operating loss | $ | (2,369 | ) | | $ | (22,863 | ) | | $ | (33,595 | ) | | $ | (164,433 | ) |

| GAAP operating margin(2) | | (1 | )% | | | (9 | )% | | | (4 | )% | | | (27 | )% |

| Non-GAAP operating margin(2) | | (1 | )% | | | (9 | )% | | | (4 | )% | | | (23 | )% |

| | | | | | | | |

| GAAP net loss | $ | (7,085 | ) | | $ | (21,165 | ) | | $ | (48,646 | ) | | $ | (204,121 | ) |

| Income tax expense (benefit) | | (608 | ) | | | (3,978 | ) | | | 418 | | | | (833 | ) |

| Interest income, interest expense and other, net | | 5,324 | | | | 2,280 | | | | 14,633 | | | | 9,403 | |

| Depreciation and amortization | | 4,513 | | | | 4,493 | | | | 13,487 | | | | 13,171 | |

| Litigation and settlement expense | | — | | | | — | | | | — | | | | 19,951 | |

| Stock-based compensation expense | | 15,893 | | | | 21,141 | | | | 47,293 | | | | 72,271 | |

| Non-recurring facility impairment and restructuring costs(1) | | — | | | | — | | | | — | | | | 11,167 | |

| Adjusted EBITDA | $ | 18,037 | | | $ | 2,771 | | | $ | 27,185 | | | $ | (78,991 | ) |

| Adjusted EBITDA margin(2) | | 6 | % | | | 1 | % | | | 3 | % | | | (11 | )% |

| | | | | | | | |

| GAAP net loss | $ | (7,085 | ) | | $ | (21,165 | ) | | $ | (48,646 | ) | | $ | (204,121 | ) |

| Litigation and settlement expense | | — | | | | — | | | | — | | | | 19,951 | |

| Non-recurring facility impairment and restructuring costs(1) | | — | | | | — | | | | — | | | | 11,167 | |

| Non-GAAP net loss | $ | (7,085 | ) | | $ | (21,165 | ) | | $ | (48,646 | ) | | $ | (173,003 | ) |

| | | | | | | | |

| GAAP cash used in operating activities | $ | (819 | ) | | $ | 8,264 | | | $ | (24,395 | ) | | $ | (19,510 | ) |

| Less: capital expenditures | | (4,687 | ) | | | (4,092 | ) | | | (15,005 | ) | | | (13,263 | ) |

| Non-GAAP free cash flow (3) | $ | (5,506 | ) | | $ | 4,172 | | | $ | (39,400 | ) | | $ | (32,773 | ) |

| (1) | In the first quarter of 2025, the Company recorded $11.2 million in impairment charges related to its operating lease right-of-use assets, and severance and other restructuring costs associated with the relocation of certain research and development activities. |

| (2) | GAAP margins, including GAAP gross margin and GAAP operating margin, and non-GAAP margins, including non-GAAP operating margin and adjusted EBITDA margin, are calculated using GAAP sales. |

| (3) | Free cash flow is a non-GAAP financial measure that the Company defines as cash provided by operating activities less capital expenditures. |

View source version on businesswire.com: https://www.businesswire.com/news/home/20261105913082/en/

Media Contact: 858-366-6900 [email protected]

Investor Contact: 858-366-6900 [email protected]

Source: Tandem Diabetes Care, Inc.

Print

Download Library

RSS Feed

Request Email Alerts

Download PDF

Planned Leadership Transition as John Sheridan Retires Following More Than a Decade of Service

SAN DIEGO--(BUSINESS WIRE)--Nov. 5, 2026-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (“Tandem” or the “Company”), a global diabetes technology company, today announced the appointment of Jeannette Bankes as president and chief executive officer (“CEO”), and a member of its Board of Directors, effective November 16, 2026. Ms. Bankes will succeed John Sheridan, who will retire at the end of 2026 after more than a decade of service to Tandem, as part of a planned leadership transition.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105587802/en/

Jeannette Bankes named President and Chief Executive Officer for Tandem Diabetes Care.

Jeannette Bankes named President and Chief Executive Officer for Tandem Diabetes Care.

Mr. Sheridan has served as Tandem’s president and CEO since 2019, after joining the Company as chief operating officer in 2013. During his tenure, Tandem launched a portfolio of automated insulin delivery solutions, while strengthening the organization’s ability to operate on a global scale, and has initiated business model changes to simplify and improve technology access. Mr. Sheridan will remain with the Company as an employee through the end of 2026, then will serve as a consultant to support a smooth transition.

Ms. Bankes brings more than 30 years of global operating experience and a strong record of translating strategy into consistent execution and growth. Her customer-focused approach and commitment to innovation align with Tandem’s mission and priorities as the Company advances its technology roadmap, broadens access and pursues sustainable, profitable growth. Her appointment follows a Board-led succession and search process designed to ensure continuity as Tandem executes its strategy.

“On behalf of the Board, I thank John for his significant contributions and dedication to our customers, employees and shareholders. He established Tandem as a global leader in diabetes technology and positioned the Company for its next phase of growth,” said Beckie Robertson, Chair of Tandem’s Board of Directors. “Jeannette is the right CEO to build on this foundation. Her broad operating experience, focus on the people we serve and ability to translate innovation into impact will be critical as we seek to deliver new technology and drive profitable growth.”

“It has been a privilege to serve as Tandem’s CEO and work alongside a dedicated organization united by our mission to improve the lives of people with diabetes, including half a million people worldwide who benefit from Tandem's technology,” said Mr. Sheridan. “Jeannette is an exceptional leader, and I am confident that she and the Tandem team have the capability, passion and commitment to guide the Company into its next chapter.”

“Tandem’s compelling mission, differentiated portfolio and global reach create a meaningful opportunity to improve the lives of more people with diabetes,” said Ms. Bankes. “I am excited to work alongside the talented people at Tandem to build on these strengths, advance the innovation pipeline and expand access to our technology. Through disciplined execution and a continued focus on customers, we can extend Tandem’s impact and deliver lasting value for the diabetes community and shareholders.”

Inducement Award

In connection with the hiring of Ms. Bankes, upon recommendation of the Compensation Committee after consultation with the committee’s independent compensation consultant, the Board approved the grant of an inducement award consisting of restricted stock units (“RSUs”), which will cover a number of shares of Tandem common stock (“Common Stock”) having an aggregate value as close as practicable to, but not exceeding, $10,000,000, based on the average closing price of the Common Stock as reported on the Nasdaq Global Market during the 15-trading-day period ending on the fifth trading day before the Grant Date (as defined below). The grant of RSUs will be effective December 15, 2026 (the “Grant Date”), and one-third of the shares subject to the RSUs will vest on the first anniversary of the Grant Date, with the remaining two-thirds vesting in eight equal quarterly installments thereafter.

The RSUs described above will be subject to the terms of Tandem’s 2023 Long-Term Incentive Plan, as amended (the “Plan”), but will be granted outside of the Plan as an inducement material to Ms. Bankes’ entering into employment with Tandem in accordance with Nasdaq Listing Rule 5635(c)(4). Such grant was intended in part to compensate Ms. Bankes for the value of unvested equity-based awards forfeited upon departure from her previous employer. Further information will be disclosed in the Company’s proxy statement for its 2027 Annual Meeting of Stockholders.

About Jeannette Bankes

Ms. Bankes is a proven leader with extensive experience at publicly traded companies in the healthcare industry, including GE HealthCare, Merck, Boston Scientific and Alcon. For more than 30 years, Ms. Bankes has held senior roles spanning product management, marketing, sales, clinical and regulatory strategy, medical affairs, operations and manufacturing. Her focus on patients and clinicians, and commitment to developing technologies that address real-world needs, have consistently translated innovation into measurable improvements in care. Most recently, she served as president and chief executive officer of GE HealthCare’s Patient Care Solutions segment, a $3.1 billion business that spans monitoring, diagnostic cardiology, maternal infant care and anesthesia solutions. In this role, Ms. Bankes drove growth and profitability across the portfolio, building on her track record of bringing new technologies to market and scaling global businesses. Previously, she served as senior vice president and president of global franchises at Alcon, overseeing product development, portfolio management and commercialization across its surgical, vision care and ocular health businesses. Ms. Bankes holds a bachelor’s degree in medical technology from Kutztown University.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit tandemdiabetes.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the leadership transition and its timing, Tandem’s strategic priorities, technology roadmap, pipeline and development timelines, commercial performance, growth, profitability and future operating results. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including risks associated with ongoing market acceptance of the Company’s products; products marketed and sold or under development by competitors; the Company’s ability to establish and sustain operations to support international sales, including expanding into additional geographies; changes in reimbursement rates or insurance coverage for the Company’s products; the Company’s ability to meet increasing operational and infrastructure requirements from higher customer interest and a larger base of existing customers; the Company’s ability to successfully commercialize its products; the Company’s ability to develop and launch new products; risks associated with the regulatory approval process internationally for new products; the potential that newer products, or other technological breakthroughs for the monitoring, treatment or prevention of diabetes, may render the Company’s products obsolete or less desirable, or may otherwise negatively impact the purchasing trends of customers; reliance on third-party relationships, such as outsourcing and supplier arrangements; global economic conditions; risks associated with the potential loss of key personnel; and other risks identified in Tandem’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Tandem undertakes no obligation to update any forward-looking statement, except as required by law.

©2026 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, the Tandem logo, Control-IQ+, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. All third-party marks are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261105587802/en/

Media Contact: 858-366-6900 [email protected]

Investor Contact: 858-366-6900 [email protected]

Source: Tandem Diabetes Care, Inc.

Print

Download Library

RSS Feed

Request Email Alerts

Prompts

Tandem Diabetes Care, Inc. (ticker TNDM), listed in United States.

ETFs Holding Tandem Diabetes Care, Inc.

ETF Weight in ETF Shares Market value As of
LGHT 0.27% 437 $ 6,594.33 Jun 30, 2026
JMEE 0.13% 220,394 $ 3.76M Nov 17, 2026
FSEG 0.10% 364 $ 5,492.76 Jun 30, 2026
FESM 0.09% 360,810 $ 5.445M Jun 30, 2026
SMDX 0.07% 5,064 $ 93.583K Nov 17, 2026
RESM 0.04% 109 $ 1,644.81 Jun 30, 2026
DFUS 0.00% 38,185 $ 668.619K Nov 12, 2026
DFAS 0.00% 30,037 $ 525.948K Nov 12, 2026
DCOR 0.00% 31,651 $ 554.209K Nov 12, 2026
DFAU 0.00% 4,269 $ 74.75K Nov 12, 2026